2D–shear-wave elastography example: MAFLD + CKD case (male, 65 years). Dahkki Zienab M. Saad (22676502)

Fáttát:

eGFR in the study participants. Dahkki Zienab M. Saad (22676502)

Fáttát:

Teams’ quotes. Dahkki Maria A. Afadapa (22683548)

Fáttát:

Implementation strategies proposed by the teams. Dahkki Maria A. Afadapa (22683548)

Fáttát:

Descriptive statistics and demographics of study participants, Ukunda and Kisumu sites, Kenya, Dec 2019–Feb 2022. Dahkki Bethel Alebel Bayrau (22676588)

Fáttát:

Clarke and Braun’s Six-Step Thematic Analysis Process. Dahkki Maria A. Afadapa (22683548)

Fáttát:

DENV and CHIKV IgG serology and RT-PCR test results among overall study population and individual study sites Ukunda and Kisumu, Kenya, Dec 2019–Feb 2022. Dahkki Bethel Alebel Bayrau (22676588)

Fáttát:

Descriptive Statistics of Research Skills and HBV-related Knowledge. Dahkki Maria A. Afadapa (22683548)

Fáttát:

Demographic and Clinical Characteristics of Study Participants. Dahkki Zienab M. Saad (22676502)

Fáttát:

Univariate analysis between DENV and CHIKV seropositivity and selected risk factors. Dahkki Bethel Alebel Bayrau (22676588)

Fáttát:

Conceptual framework integrating cultural constructs of PEN-3 model with participatory research strategies—Crowdsourcing, Designathon (Apprenticeship), and PAR—to co-create, implem... Dahkki Maria A. Afadapa (22683548)

Fáttát:

Seroconversion of DENV and CHIKV among study participants in Kisumu and Ukunda, Kenya, Dec 2019 – Feb 2022. Dahkki Bethel Alebel Bayrau (22676588)

Fáttát:

Stratification of Liver Stiffness according to eGFR in the MAFLD group. Dahkki Zienab M. Saad (22676502)

Fáttát:

Overview of the Designathon stages. Dahkki Maria A. Afadapa (22683548)

Fáttát:

Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022. Dahkki Bethel Alebel Bayrau (22676588)

Fáttát:

Kaplan Meier survival curves for new DENV seropositivity during the 2-year study period from Dec 2019 – Feb 2022.. Dahkki Bethel Alebel Bayrau (22676588)

Fáttát:

Medication-inclusive multivariable logistic regression for MAFLD. Dahkki Zienab M. Saad (22676502)

Fáttát:

Receiver operating characteristic (ROC) curve analysis comparing the performance of non-invasive fibrosis scores in MAFLD patients. Dahkki Zienab M. Saad (22676502)

Fáttát:

Comparison of Non-invasive Liver Fibrosis Scores. Dahkki Zienab M. Saad (22676502)

Fáttát:

A. Violin plots showing eGFR distribution in MAFLD (red) vs. non-MAFLD (blue) groups. Dahkki Zienab M. Saad (22676502)

Fáttát: